A phase II study of sequential decitabine and rapamycin in acute myelogenous leukemia.
暂无分享,去创建一个
M. Azadniv | J. Liesveld | M. Becker | A. Baran | K. O'Dwyer | J. Mendler | K. Nedrow | K. P. Loh | Haley Misch
[1] H. Döhner,et al. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. , 2021, The Lancet. Oncology.
[2] Yi Zheng,et al. Adaptive responses to mTOR gene targeting in hematopoietic stem cells reveal a proliferative mechanism evasive to mTOR inhibition , 2020, Proceedings of the National Academy of Sciences.
[3] H. Döhner,et al. Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Tormo,et al. Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing? , 2020, Leukemia.
[5] T. Žvirblis,et al. Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax‐based salvage therapies , 2020, European journal of haematology.
[6] Xu Huang,et al. Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence , 2020, Journal of clinical medicine.
[7] A. Letai,et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. , 2020, The New England journal of medicine.
[8] Xiaomei Ma,et al. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. , 2020, Blood advances.
[9] A. Gural,et al. Venetoclax is safe and efficacious in relapsed/refractory AML , 2020, Leukemia & lymphoma.
[10] H. Reikvam,et al. The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells , 2020, International journal of molecular sciences.
[11] G. Madlambayan,et al. The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia , 2020, Haematologica.
[12] Qi Zhang,et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. , 2020, Blood.
[13] F. Ferrara,et al. Current Therapeutic Results and Treatment Options for Older Patients with Relapsed Acute Myeloid Leukemia , 2019, Cancers.
[14] M. Konopleva,et al. Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. , 2019, The Lancet. Haematology.
[15] A. Cashen. 10-day decitabine schedule in acute myeloid leukaemia: no extra bang for the buck. , 2019, The Lancet. Haematology.
[16] J. Scandura,et al. Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia , 2018, Haematologica.
[17] M. Konopleva,et al. Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies , 2018, American journal of hematology.
[18] Shuang Liu,et al. Targeting PI3K, mTOR, ERK, and Bcl‐2 signaling network shows superior antileukemic activity against AML ex vivo , 2018, Biochemical pharmacology.
[19] J. Liesveld,et al. Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML. , 2017, Blood reviews.
[20] R. Larson,et al. Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia , 2017, Leukemia & lymphoma.
[21] Bob Löwenberg,et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.
[22] S. Grant,et al. Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation , 2015, Haematologica.
[23] S. Capitani,et al. Targeting PI3K/AKT/mTOR network for treatment of leukemia , 2015, Cellular and Molecular Life Sciences.
[24] S. Grant,et al. Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML. , 2014, Physiological genomics.
[25] J. Liesveld,et al. A phase I study of decitabine and rapamycin in relapsed/refractory AML. , 2013, Leukemia research.
[26] A. Redig,et al. Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors , 2011, Clinical Cancer Research.
[27] W. Shannon,et al. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. , 2010, Blood.
[28] J. Dipersio,et al. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] J. McCubrey,et al. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia , 2009, Expert opinion on investigational drugs.
[30] Q. Rao,et al. Aberrant expression of TSC2 gene in the newly diagnosed acute leukemia. , 2009, Leukemia research.
[31] H. Koeffler,et al. Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells , 2008, Leukemia.
[32] S. Chakraborty,et al. Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma , 2008, BMC Cancer.
[33] M. Grever,et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] S. Morrison,et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells , 2006, Nature.
[35] G. Laurent,et al. Antileukemic activity of rapamycin in acute myeloid leukemia. , 2005, Blood.
[36] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.